MARKET

AKTX

AKTX

Akari Therapeutics Plc
NASDAQ
8.05
+0.51
+6.72%
Opening 10:06 08/17 EDT
OPEN
7.68
PREV CLOSE
7.54
HIGH
8.10
LOW
7.68
VOLUME
20.90K
TURNOVER
--
52 WEEK HIGH
49.60
52 WEEK LOW
3.015
MARKET CAP
15.67M
P/E (TTM)
-0.0190
1D
5D
1M
3M
1Y
5Y
1D
Akari Therapeutics Reaffirmed Buy as Analyst Keeps $27 Price Target on Advancing Trop2 ADC and Strengthened PH1 Platform
TipRanks · 1h ago
Weekly Report: what happened at AKTX last week (0810-0814)?
Weekly Report · 6h ago
Akari Therapeutics reports Q2 results
Seeking Alpha · 3d ago
Akari Therapeutics Says Strategic Research Collaboration With Whitehawk Therapeutics Expands Potential Application Of Akari’s PH1 Platform Into Dual-Payload ADCs
Benzinga · 3d ago
Akari Therapeutics Reports Second Quarter 2026 Financial Results and Highlights Progress of AKTX-101 Towards Phase 1 and Strategic Collaboration for Its ADC Payload Platform
Barchart · 4d ago
Weekly Report: what happened at AKTX last week (0803-0807)?
Weekly Report · 08/10 10:23
Weekly Report: what happened at AKTX last week (0727-0731)?
Weekly Report · 08/03 10:23
Why Amazon Shares Are Trading Higher By 12%; Here Are 20 Stocks Moving Premarket
Benzinga · 07/31 08:50
More
About AKTX
Akari Therapeutics, Plc is a biotechnology company developing precision bifunctional antibody drug conjugates (ADC) for the treatment of cancer. Utilizing its ADC discovery platform, it generates bifunctional ADC candidates and optimizes them based on the desired application to target a range of cancers. Its lead candidate, AKTX-101, targets the TROP2 receptor on cancer cells, and with a proprietary linker, delivers its novel PH1 payload directly into the tumor. PH1 is a novel bifunctional payload that is designed to disrupt RNA splicing within cancer cells, inducing tumor-specific cell death while generating immunostimulatory effects and minimizing off-target toxicity. Its pipeline includes AKTX-101 and AKTX-102, a discovery-stage ADC that pairs PH1 with an undisclosed target antibody. It is pursuing research on two additional novel payloads, such as PH5 and PH6. It also has an ADC Platform for oncology and PHP-303 program for genetic disease, liver disease and inflammation.

Webull offers Akari Therapeutics PLC (ADR) stock information, including NASDAQ: AKTX real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, AKTX stock news, and many more online research tools to help you make informed decisions. Trade stocks for 0 commission and 0 contract fees on the web version for easy and convenient access, or download the Webull app and trade on the go.

You can practice and explore trading AKTX stock methods without spending real money on the virtual paper trading platform.